A5011827144- Acute Myeloid Leukemia Research
- Retinoids in leukemia and cellular processes
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Advanced biosensing and bioanalysis techniques
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Lung Cancer Treatments and Mutations
- Antioxidant Activity and Oxidative Stress
- Viral-associated cancers and disorders
- Drug-Induced Ocular Toxicity
- Hemoglobinopathies and Related Disorders
- CNS Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
- Neutropenia and Cancer Infections
- Kruppel-like factors research
- Clinical practice guidelines implementation
- Blood disorders and treatments
- Estrogen and related hormone effects
University Hospital Heidelberg
2013-2023
Heidelberg University
2013-2023
University of Mannheim
1996-2023
University Medical Centre Mannheim
2013-2023
Medizinische Fakultät Mannheim
2009-2010
University Medical Center Freiburg
2009
Universität Ulm
2004-2009
University of Regensburg
2006-2008
University of Cologne
2006-2008
University of Münster
1987-2008
The purpose of the study was to assess contribution age and disease variables outcome untreated patients with acute myeloid leukemia (AML) receiving varying intensive induction chemotherapy.Patients 16 85 years primary AML, known karyotype, uniform postremission chemotherapy enrolled onto two consecutive trials were eligible randomly assigned either a standard-dose (cytarabine, daunorubicin, 6-thioguanine) high-dose (cytarabine mitoxantrone) combination, or courses combination. Subgroups...
The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical biologic markers were for their impacts on outcome.One hundred nine enrolled, 103 received at least one dose alemtuzumab. After escalation, was administered subcutaneously 30 mg three times weekly up to 12 weeks. Response assessed every 4 weeks during treatment quarterly thereafter.The overall response rate 34% (complete...
On the basis of cytomorphology according to French-American-British (FAB) classification, we evaluated prognostic impact dysplastic features and other parameters in de novo acute myeloid leukemia (AML). We also assessed clinical significance recently introduced World Health Organization (WHO) classification for AML, which proposed dysplasia as a new parameter classification.We analyzed prospectively 614 patients with all whom were diagnosed by central morphologic analysis treated within...
Intensification by high-dose cytarabine in postremission or induction therapy and prolonged maintenance are established strategies to improve the outcome patients with acute myeloid leukemia (AML). Whether additional intensification can add this effect has not yet been determined.A total of 1,770 (age 16 85 years) de novo secondary AML high-risk myelodysplastic syndrome (MDS) were randomly assigned upfront for containing one course standard dose cytarabine, two courses same step received...
To examine the efficacy of prolonged maintenance chemotherapy versus intensified consolidation therapy for patients with acute myeloid leukemia (AML).Eight hundred thirty-two (median age, 54 years; range, 16 to 82 years) de novo AML were randomly assigned receive 6-thioguanine, cytarabine, and daunorubicin (TAD) plus cytarabine mitoxantrone (HAM; 3 g/m2 [age < 60 years] or 1 > = x 6) induction, TAD consolidation, monthly modified years, TAD-HAM-TAD one course intensive sequential HAM (S-HAM)...
In order to evaluate the natural history of essential thrombocythaemia (ET), clinical data and prognostic factors 143 patients with ET were retrospectively analysed (mean observation time 6.1 ± 4.6 years). 42 early phase disease initial platelet counts between 250 600 × 10 9 /l was assessed. most cases, suggested by symptoms (79%) increased megakaryopoiesis (95%) abnormal megakaryocytes in bone marrow histology ( n = 34) cytology 5). Other myeloproliferative disorders reactive thrombocytosis...
Abstract BACKGROUND. In patients with advanced‐stage follicular lymphoma (FL) and mantle cell (MCL), conventional chemotherapy remains a noncurative approach, no major improvement in overall survival has been achieved recent decades. METHODS. The German Low‐Grade Lymphoma Study Group performed randomized trial comparing combined cyclophosphamide, vincristine, doxorubicin, prednisone (CHOP) mitoxantrone, chlorambucil, (MCP) as first‐line therapy for FL or MCL. RESULTS. Three hundred...